Health insurers will only reimburse some flu sufferers for the antiviral medicine Tamiflu, health authorities have said.
This content was published on
1 minute
The medicine, used to treat the H1N1 virus, will be made available free from August 1 to hospital patients, children aged over three and adults aged over 65. A box of ten Tamiflu pills costs around SFr80 ($74).
The Federal Health Office confirmed on Sunday that even though pregnant women were a risk group for the virus, they would not be reimbursed for the drug for the time being.
Swissmedic, the agency that authorises therapeutic products, has not yet approved use of Tamiflu in children under three.
Tamiflu is one of two anti-viral drugs, along with Relenza, said to be effective against the so-called swine flu. Each pack of Tamiflu, also known as oseltamivir, is enough for one course of treatment for the viral infection.
Swiss health authorities have warned that up to two million people in Switzerland may be affected by swine flu – almost one in four of the population.
The pandemic spread globally in less than two months and has infected people in 160 countries.
swissinfo.ch and agencies
Popular Stories
More
Climate solutions
Switzerland turns train tracks into solar power plants
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Pharmaceuticals drive growth at Novartis
This content was published on
Novartis said net sales for the first six months were $20.3 billion (SFr21.87 billion), an increase of eight per cent in local currencies but a decline of two per cent in dollars over the comparable period last year. Net income for the first half was down by 12 per cent at $4.02 billion. Announcing its…
This content was published on
The company said the programme should ensure that Tamiflu is available to them if the World Health Organization declares an influenza pandemic, or for the management of a novel influenza strain defined by the WHO that has significant pandemic potential. In a statement, the Basel-based company said on Wednesday it would produce and store Tamiflu…
This content was published on
Nearly 20 per cent of the country’s population could be infected but authorities have characterised the predicted increase in cases of the A/H1N1 virus as more an organisational challenge than a major threat to public health. “We expect up to five times more flu patients than during the country’s normal flu season,” Federal Health Office…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.